Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Angelo Delmonte
Observed name:
A. Delmonte
Institution:
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Observed institution:
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
ORCID:
0009-0004-2629-8519
Observed ORCID:
0009-0004-2629-8519
OpenAlex ID:
A5069655328
Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK–Inhibitor-Naive ALK+ Non–Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study
2022
·
Myung J. Ahn
, Hye R. Kim
, et al.
·
Clinical Lung Cancer
·
49
PDF
Single-Agent Divarasib in Patients With KRAS G12C –Positive Non–Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study
2025
·
Adrian G. Sacher
, Wilson H. Miller
, et al.
·
Journal of Clinical Oncology
·
39
Real-World Safety and Outcome of First-Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort (“PEMBROREAL” Study)
2024
·
Alessandro Cafaro
, Flavia Foca
, et al.
·
Cancers
·
13
MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
2025
·
Federico Cappuzzo
, Biagio Ricciuti
, et al.
·
Clinical Cancer Research
·
6
Genomic and Transcriptomic Profiles in Smokers and Never-Smokers Lung Squamous Cell Carcinoma Patients
2025
·
Matteo Canale
, Alessandra Virga
, et al.
·
Lung Cancer Targets and Therapy
·
5
PDF
First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study
2024
·
Duncan A. Wheatley
, Rossana Berardi
, et al.
·
Cancer Research Communications
·
2
PDF
Clinicopathological Features of Non-Small Cell Lung Carcinoma with NRAS Mutation
2025
·
Andrea Ambrosini-Spaltro
, Claudia Rengucci
, et al.
·
Journal of Personalized Medicine
PDF
Supplementary Table S6 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
2025
·
Federico Cappuzzo
, Biagio Ricciuti
, et al.
Supplementary Figure S13 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
2025
·
Federico Cappuzzo
, Biagio Ricciuti
, et al.
Supplementary Figure S1 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
2025
·
Federico Cappuzzo
, Biagio Ricciuti
, et al.
Supplementary Figure S14 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
2025
·
Federico Cappuzzo
, Biagio Ricciuti
, et al.
Supplementary Table S7 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
2025
·
Federico Cappuzzo
, Biagio Ricciuti
, et al.
Supplementary Table S3 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
2025
·
Federico Cappuzzo
, Biagio Ricciuti
, et al.
Supplementary Appendix S2 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
2025
·
Federico Cappuzzo
, Biagio Ricciuti
, et al.
Supplementary Appendix S1 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
2025
·
Federico Cappuzzo
, Biagio Ricciuti
, et al.
Supplementary Figure S4 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
2025
·
Federico Cappuzzo
, Biagio Ricciuti
, et al.
Supplementary Figure S9 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
2025
·
Federico Cappuzzo
, Biagio Ricciuti
, et al.
Supplementary Figure S3 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
2025
·
Federico Cappuzzo
, Biagio Ricciuti
, et al.
Supplementary Figure S7 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
2025
·
Federico Cappuzzo
, Biagio Ricciuti
, et al.
Supplementary Table S4 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
2025
·
Federico Cappuzzo
, Biagio Ricciuti
, et al.
Supplementary Figure S8 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
2025
·
Federico Cappuzzo
, Biagio Ricciuti
, et al.
Supplementary Table S2 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
2025
·
Federico Cappuzzo
, Biagio Ricciuti
, et al.
Supplementary Figure S6 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
2025
·
Federico Cappuzzo
, Biagio Ricciuti
, et al.
Supplementary Figure S11 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
2025
·
Federico Cappuzzo
, Biagio Ricciuti
, et al.
Supplementary Table S1 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
2025
·
Federico Cappuzzo
, Biagio Ricciuti
, et al.
Show more works
View as search
Works count:
50
Citation count:
114
H-index:
5
I10-index:
3
Year
Topic
Type